
    
      This is a randomized placebo-controlled clinical trial to evaluate the safety and
      effectiveness to modify gut microbiota, bacterial translocation, immune activation and
      markers of endothelial dysfunction of a dietary supplement (prebiotics + glutamine) during a
      period of six weeks. The study will enroll four cohorts: 1) HIV-infected, treatment naive
      individuals; 2) HIV-infected subjects, currently on ART, with >350 CD4+ T-cells/uL; 3)
      HIV-infected subjects, currently on ART, with <350 CD4+ T-cells/uL; 4) HIV negative healthy
      controls.
    
  